Table 1.
Characteristics of the analysed trials.
| Study/Reference | Primary endpoint | Number of patients experimental arm | Number of patients control arm | Experimental drug/control arm | PD-L1 positivity |
|---|---|---|---|---|---|
| CheckMate 214/5 | OS, PFS, ORR | 550 | 546 | Nivolumab+ipilimumab/ Sunitinib | ⩾1% Dako PD-L1 IHC 28-8 pharmDx test |
| IMmotion150/6 | PFS | 101/103 | 101 | Atezolizumab+bevacizumab/ Atezolizumab/Sunitinib | ⩾1% (SP142 IHC assay) |
| IMmotion151/7 | OS/PFS | 454 | 461 | Atezolizumab+bevacizumab/ Sunitinib |
⩾1% (SP142 IHC assay) |
| KEYNOTE-426/9 | OS, PFS |
432 | 429 | Pembrolizumab+axitinib/ Sunitinib |
NR |
| JAVELIN Renal 101/8 | OS, PFS | 442 | 444 | Avelumab+axitinib/ Sunitinib |
⩾1% Ventana PD-L1 (SP263) assay |
ORR, objective response rate; OS, overall survival; PFS, progression free survival.